title: Industry progress report on neuro-oncology: a biotech update.
abstract: With steadily rising revenue and large numbers of clinical trials utilizing novel treatment strategies, the field of neuro-oncology is at the core of the growing cancer therapy industry. In June 2012, the Weill Cornell Brain and Tumor Center hosted the first Brain Tumor Biotech Summit as a forum for fostering and encouraging collaboration between researches and investors to accelerate novel treatments for brain cancer. This event brought together neuro-oncologists, neurosurgeons, academicians, entrepreneurs, non-profits, CEOs and investors in an attempt to bring innovative treatments and concepts to the fore. Specific subjects presented at the meeting included new surgical devices and delivery techniques, targeted therapeutics, immunotherapy, and stem cell biology. The mission of the summit was to provide opportunities for researchers in neuro-oncology to directly interact with leaders from the investment community with insight into the commercial aspects of our work. Our shared goal is to shorten the time for basic science ideas to be translated into the clinical setting. The following serves as a progress report on the biotech industry in neuro-oncology, as presented at the Brain Tumor Biotech Summit.
authors: Department of Neurological Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY 10021, USA.
authors: Jessica S
authors: JS
authors: Haber
authors: Matei A
authors: MA
authors: Banu
authors: Ashley
authors: A
authors: Ray
authors: Kartik
authors: K
authors: Kesavabhotla
authors: John A
authors: JA
authors: Boockvar
mesh_terms: D001709:Biotechnology / Q000639:trends*; D001932:Brain Neoplasms / Q000175:diagnosis / Q000628:therapy*; D004345:Drug Industry; D006801:Humans; D058990:Molecular Targeted Therapy; D004364:Pharmaceutical Preparations; D058028:Research Report
chemical_list: D004364:Pharmaceutical Preparations